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Triazolophostins: a library of novel and potent
agonists of IP3 receptors†
Amol M. Vibhute,a Vera Konieczny,b Colin W. Taylorb and Kana M. Sureshan*a
IP3 receptors are channels that mediate the release of Ca
2+ from the intracellular stores of cells stimulated
by hormones or neurotransmitters. Adenophostin A (AdA) is the most potent agonist of IP3 receptors, with
the β-anomeric adenine contributing to the increased potency. The potency of AdA and its stability
towards the enzymes that degrade IP3 have aroused interest in AdA analogs for biological studies. The
complex structure of AdA poses problems that have necessitated optimization of synthetic conditions for
each analog. Such lengthy one-at-a-time syntheses limit access to AdA analogs. We have addressed this
problem by synthesizing a library of triazole-based AdA analogs, triazolophostins, by employing click
chemistry. An advanced intermediate having all the necessary phosphates and a β-azide at the anomeric
position was reacted with various alkynes under Cu(I) catalysis to yield triazoles, which upon deprotection
gave triazolophostins. All eleven triazolophostins synthesized are more potent than IP3 and some are
equipotent with AdA in functional analyses of IP3 receptors. We show that a triazole ring can replace
adenine without compromising the potency of AdA and provide facile routes to novel AdA analogs.
I. Introduction
Many biological processes are regulated by changes in the
intracellular concentration of Ca2+.1 A major pathway for these
Ca2+ signals is the release of Ca2+ from intracellular stores
within the endoplasmic reticulum (ER) via IP3 receptors
(IP3R).
2 IP3R are a family of intracellular Ca
2+ channels that are
expressed largely in ER membranes.3 IP3 (Fig. 1A, 1) is pro-
duced when cell-surface receptors stimulate phospholipase C
activity. IP3 then binds to IP3R causing its channel to open
and release Ca2+ into the cytosol.4 The ability of IP3 to interact
with IP3R is terminated by its dephosphorylation or phos-
phorylation by specific 5-phosphatase and 3-kinase enzymes.5
While terminating the Ca2+-mobilizing ability of IP3, these
steps also initiate recycling of inositol to the lipid from which
IP3 is generated and the synthesis of more complex bioactive
phosphoinositols including the pyrophosphates,6 many of
which have been recent synthetic targets.7 Adenophostin A
(AdA), a fungal metabolite isolated from the culture broth of
Penicillium brevicompactum, is a more potent agonist than IP3
of IP3R.
8 Moreover, AdA is resistant to the enzymes that metab-
olize IP3. Many analogs of AdA have been synthesized to
address structure–activity relationships and the determinants
of the increased potency of AdA.9 These studies revealed that
the three phosphates and 2″-OH (color coded in Fig. 1A, 2),
which structurally mimic the essential pharmacophore of
IP3,
10 are essential for AdA activity. The nucleobase/surrogate
with β-stereochemistry is indispensible for the enhanced
potency.9b,11
Recent studies have suggested that a cation–π interaction
between adenine and a cationic residue (Arg504) of the IP3R
might be responsible for the increased potency of AdA.9b,12
Additional base-modified analogs of AdA would be useful in
both testing this proposal and as potent and metabolically
stable agonists of IP3R to probe Ca
2+ signaling mechanisms.
The major hurdle in developing such AdA analogs lies in
the synthesis of these structurally complex base-modified
analogs (disaccharide nucleotides).9e,13 The traditional syn-
thesis involves N-glycosylation of a nucleobase with an ortho-
gonally protected disaccharide derivative followed by
chemoselective demasking and phosphorylation of specific
hydroxyl groups in the nucleoside (Fig. 1B). This early intro-
duction of the nucleobase necessitates an almost individually
tailored synthesis (branching at an early stage of synthesis) for
†Electronic supplementary information (ESI) available: Synthetic procedures
and spectral data for all new compounds, crystal data for disaccharide 4 and
details of the docking study. CCDC 1022279. For ESI and crystallographic data in
CIF or other electronic format see DOI: 10.1039/c5ob00440c
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each base-modified analog. Further complications arise from
the lack of a generally applicable method for glycosylation and
phosphorylation of such complex molecules. For instance gly-
cosylation of nucleobases is challenging with respect to yield14
and regioselectivity,13b,15 and each glycosylation condition has
to be optimized individually. Chemoselective O-phosphoryl-
ation in the presence of nucleobases having nucleophilic
groups/sites is also challenging.16 Thus synthesis of analogs by
a one-at-a-time method is cumbersome, time-consuming and
impractical. We herein report a general strategy for making a
combinatorial library of structurally diverse AdA analogs that
are potent agonists of IP3R.
II. Results and discussion
Imidophostin (Fig. 2A), though weaker than AdA, is more
potent than IP3, suggesting that even a 5-membered aromatic
heterocyclic ring can be a partial functional mimic of adenine.
As triazole is isosteric with imidazole, we envisioned that tria-
zole-based AdA analogs would also be potent agonists of IP3R.
This and the earlier reports on the use of click reaction in bio-
logically important molecules17 prompted us to adopt azide–
alkyne click chemistry to make a library of triazolophostins,
AdA analogs wherein the nucleobase is replaced by substituted
triazoles. These molecules can easily be prepared by reacting
appropriately protected tris-phosphate derivative II having an
azide at the anomeric position with aryl or heteroaryl alkynes
under Cu(I) catalysis (Fig. 2B). Such an approach would solve
three major issues associated with conventional AdA analog
synthesis: (i) ensure the necessary β-anomeric stereochemistry
of the base-surrogate, (ii) as the triazole-based base-surrogate
is introduced only at the penultimate step (after phosphoryl-
ation), the interference of nucleobases during phosphorylation
can be avoided and (iii) diversification at the penultimate step
provides access to many structurally diverse analogs from a
common advanced intermediate.
We have synthesized orthogonally protected disaccharide 4
in thirteen steps from D-glucose and D-xylose in a convergent
manner as reported previously.18 Acetolysis19 of the ketal 4
gave tetraacetate 5 as anomeric mixtures in very good yield.
Lewis acid catalysed azidation of the acetate 5 gave anomeri-
cally pure β-azide 6.20 Methanolysis of the acetate groups in 6
provided the triol 7 in excellent yield. Phosphitylation of the
triol 7 using phosphoramidite followed by in situ oxidation
using m-CPBA provided the fully protected trisphosphate 8.
Compound 8 with three phosphates in their appropriate rela-
tive positions and β-oriented azide is the common advanced
intermediate for coupling with diﬀerent alkynes. Copper(I)
catalysed click reaction of azide 8 with various alkynes pro-
vided fully protected triazolophostins 9a–k. As the reaction is
catalyzed by copper(I), 1,4-substituted triazoles21 were obtained
exclusively in all the cases. Global removal of the benzyl pro-
tecting groups by transfer hydrogenolysis provided triazolo-
Fig. 2 (A) Imidophostin and triazolophostins. (B) Retrosynthetic analysis
of triazolophostins.
Fig. 1 (A) Molecular structures of IP3 (1) and AdA (2); (B) conventional
synthesis of AdA-analogs. The question marks represent the complexity
of conventional syntheses.
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phostins 10a–k in very good yields (Scheme 1). Though in a
recent elegant communication, Potter et al. reported a func-
tionally active triazole based cADPR analog,22 ours is the first
report on the use of click chemistry to generate a library of
IP3R agonists.
The abilities of the newly synthesized ligands to evoke Ca2+
release via IP3R were assessed using permeabilized cells that
express only type 1 IP3R.
23 A low-aﬃnity Ca2+ indicator trapped
within the ER allowed the eﬀects of IP3 to be directly measured
using a fluorescence plate-reader equipped to allow automated
additions. All the triazolophostins fully release the IP3-sensi-
tive Ca2+ stores and all are more potent than IP3 (Table 1,
Fig. 3). It is interesting to note that the parent analog triazolo-
phostin 10a having only the five-membered ring is 13-fold
more potent than IP3. This remarkable AdA-like potency of 10a
suggests that a single triazole ring can eﬀectively replace the
adenine base in AdA without compromising potency. In con-
trast, imidophostin was previously reported to be only slightly
(1.3-fold) more potent than IP3, and it was therefore suggested
that a fused bicyclic nucleobase/surrogate is essential for
AdA-like potency.18a Among all triazolophostins, the 3-fluoro
derivative 10f is the most potent, and equipotent to AdA: it is
the most potent AdA analog without a purine nucleobase. Of
the several AdA analogs reported in the literature, very few
match the potency of AdA.9c,12b,13b,14,18a,24,25 In this context,
our late-stage diversification method is important because
it allows many potent analogs to be made in an easy and
combinatorial way from the same advanced intermediate.
The docking study suggests that triazolophostin 10a and
AdA exhibit similar interactions with the IP3-binding core of
IP3R1 (IBC, residues 224–604).
24 The triazolyl ring of 10a
forms a cation–π interaction with Arg504 similar to the pro-
posed interaction between the adenine of AdA and Arg504.
This supports previous reports that a cation–π interaction
between the base and IP3R contributes to the increased
potency of AdA and analogs.9c,24 All other triazolophostin
analogs showed a similar interaction. The small diﬀerences in
activity among these analogs seem to arise from steric, rather
than electronic factors. For instance, attaching aromatic rings
with diﬀerent electrostatic surface potentials to the triazole
ring did not cause any systematic change in biological activity.
The fact that all the analogs are both more potent than IP3,
and show a conserved cation–π interaction between the triazole
ring and Arg504 suggests that this critical interaction is
unaﬀected by aromatic substitution, irrespective of the elec-
tronic nature of the aromatic substituent. The single bond con-
nection between the triazole ring and the substituent
(aromatic ring) allow torsional freedom (freely rotatable) and
hence the sterically favorable non-coplanar conformation of
the two aromatic rings. As a result of such non-coplanarity
(lack of conjugation), the electron density on the triazole ring
cannot be influenced by the aromatic unit. This could be the
reason why there is no clear trend in activity when the aro-
matic ring is modified with electron-deficient or electron-rich
substituents.
One reason for the increased potency of AdA is believed to
be its conformational flexibility allowing it to adopt an optimal
conformation for binding to IP3R.
26 The additional confor-
mational freedom due to the single bond linkage of this
hetero-biaryl unit (rather than fused rings in AdA) allows the
second ring to orient to an electronically favorable position,
such that it can have additional electrostatic interactions.
Docking results suggest that the most potent analog, 10f, has
additional interactions between F and IP3R side-chains (D566,
Q565 and Q507) that may enhance its activity (Fig. 4).
III. Conclusions
In conclusion, addressing the problems associated with con-
ventional one-at-a-time synthesis of AdA analogs, we have syn-
thesized a library of new analogs using azide–alkyne click
chemistry. The simple reaction conditions, high yield and
atom-economy of the click reaction to install base-surrogates
are advantageous over the conventional Vorbruggen method of
installation of a nucleobase. By this easy and rapid method, we
Scheme 1 Synthesis of triazolophostins. (a) H2SO4-silica, Ac2O, DCM,
rt, 12 h, 90%; (b) TMSN3, AlCl3, DCM, 0 °C, 10 min, 99%; (c) NaOMe,
MeOH, rt, 30 min, 96%; (d) (i) (iPr)2NP(OBn)2, ImOTf, DCM, rt, 1 h, (ii)
m-CPBA, −78 °C, 45 min, 90%; (e) (i) trimethylsilylacetylene, Cu, CuSO4,
H2O :
tBuOH, rt, 12 h; (ii) TBAF, THF, rt, 2 h, (95% for two steps); (f )
alkyne, Cu, CuSO4, H2O :
tBuOH, rt, 12 h, 48–97%; (g) cyclohexene, Pd-
(OH)2, MeOH : H2O, 80 °C, 4 h, Bn = benzyl, Ac = acetyl, Me = methyl.
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have generated a variety of ligands with diverse structures from
a common advanced intermediate. All the analogs synthesized
by this method are more potent than IP3 and some (10a, 10f,
10g, 10k) are as potent as AdA. Though replacement of purines
with pyrimidines or other aromatic groups is reported to give
agonists that are more potent than IP3, none of the previously
reported non-purinated AdA analogs was as potent as AdA. We
have shown that AdA-like potency can be achieved without a
nucleobase. Our study reveals that a five-membered aromatic
ring, triazole, is suﬃcient as a base surrogate to exhibit AdA-
like potency. Easy access to potent, non-metabolizable ligands
of IP3R and the ease of conjugation with reporter groups such
as fluorescent probes, photoaﬃnity probes, etc. oﬀers avenues
for advanced biological exploration. This report that triazoles
can be functional mimics of nucleobases has broader impli-
cation and might trigger such attempts in other nucleobase-
derived signaling molecules.
IV. Experimental section
1. General methods
Chromatograms were visualized under UV light and by
dipping plates into either phosphomolybdic acid in MeOH or
anisaldehyde in ethanol, followed by heating. 1H NMR, COSY,
NOESY and HMQC spectra were recorded on a 500 MHz NMR
spectrometer. Proton chemical shifts are reported in ppm (δ)
relative to the internal standard tetramethylsilane (TMS,
Table 1 Ca2+ release via IP3R evoked by triazolophostins
a
Ligand R = pEC50 EC50 (nM) EC50 w.r.t. 1 Max. response (%)
IP3 (1) 6.75 ± 0.08 178 1 73 ± 3
AdA (2) 8.05 ± 0.04 9 20 73 ± 2
10a H 7.87 ± 0.00 13 13 71 ± 1
10b 7.75 ± 0.03 18 10 72 ± 2
10c 7.81 ± 0.05 15 11 65 ± 3
10d 7.77 ± 0.03 17 10 64 ± 1
10e 7.70 ± 0.07 20 9 75 ± 4
10f 8.00 ± 0.03 10 18 69 ± 1
10g 7.86 ± 0.04 14 13 71 ± 2
10h 7.64 ± 0.01 23 8 67 ± 2
10i 7.45 ± 0.03 35 5 65 ± 1
10j 7.78 ± 0.03 17 11 68 ± 2
10k 7.89 ± 0.02 13 14 70 ± 1
a Results show the maximal Ca2+ release (% of Ca2+ content of intracellular stores), EC50 and pEC50 values (means ± SEM from at least 3
experiments), and EC50 relative to 1 (EC
IP3
50 /EC
analog
50 ). Hill coeﬃcients were not significantly diﬀerent from 1.
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δ 0.0 ppm) or with the solvent reference relative to TMS
employed as the internal standard (CDCl3, δ 7.26 ppm; D2O,
δ 4.79 ppm). Data are reported as follows: chemical shift (mul-
tiplicity [singlet (s), doublet (d), doublet of doublet (dd),
triplet (t), quartet (q), and multiplet (m)], coupling constants
[Hz], integration and peak identification). All NMR signals
were assigned on the basis of 1H NMR, 13C NMR, COSY and
HMQC experiments. 13C spectra were recorded with complete
proton decoupling. Carbon chemical shifts are reported in
ppm (δ) relative to TMS with the respective solvent resonance
as the internal standard. All NMR data were collected at 25 °C.
The concentration of the compounds for 1H NMR was 5 mg
per 0.5 mL and for 13C NMR it was 20 mg per 0.5 mL for pro-
tected compounds and 5–7 mg per 0.5 mL for final com-
pounds in the case of 1H and 13C NMR. Each triazolophostin
(10a–k) was quantified using the Briggs’s/Ames’s phosphate
assay. Melting point was determined using melting point
apparatus and is uncorrected. Flash column chromatography
was performed using a silica gel 230–400 mesh. Wherever
needed, the reactions were carried out under an argon or nitro-
gen atmosphere employing oven dried glassware.
X-ray intensity data measurements of freshly grown crystals
of 4 were carried out at 293–296 K on a Bruker-KAPPA APEX II
CCD diﬀractometer with graphite-monochromatized (MoKα =
0.71073 Å) radiation. The X-ray generator was operated at
50 kV and 30 mA. Data were collected with a scan width of 0.3°
at diﬀerent settings of φ (0°, 90° and 180°) keeping the sample
to detector distance fixed at 40 mm and the detector position
(2θ) fixed at 24°. The X-ray data collection was monitored by
SMART program. All the data were corrected for Lorentzian,
polarization and absorption eﬀects using SAINT and SADABS
programs. SHELX-97 was used for structure solution and full
matrix least-squares refinement on F2. Molecular and packing
diagrams were generated using Mercury-3.1. Geometrical
calculations were performed using SHELXTL and PLATON.
2. Synthesis of 1,2,3′,4′-tetra-O-acetyl-2′,5,6′-tri-O-benzyl-3-O-
α-D-glucopyranosyl-D-ribofuranose (5)
To a solution of disaccharide 4 (1.0 g, 1.41 mmol) and Ac2O
(0.4 mL, 4.24 mmol) in dry DCM (20 mL), 0.05 g of freshly pre-
pared H2SO4-silica
19 was added. The reaction mixture was
stirred at room temperature for 12 h under a nitrogen atmos-
phere and the reaction was monitored using TLC. When the
starting material disappeared, the reaction mixture was
quenched by the addition of solid NaHCO3. The solid material
was filtered oﬀ and the organic layer was washed with satu-
rated aqueous NaHCO3 solution. The organic layer was dried
over Na2SO4 and evaporated under reduced pressure. The
crude product thus obtained was purified by flash column
chromatography using 40% ethyl acetate in petroleum ether as
the eluent to obtain the known18a tetraacetate 5 (0.96 g, 90%)
as a sticky mass.
3. Synthesis of 2,3′,4′-tri-O-acetyl-2′,5,6′-tri-O-benzyl-3-O-α-D-
glucopyranosyl-β-D-ribofuranosyl azide (6)
To a solution of tetraacetate 5 (0.51 g, 0.68 mmol) and TMSN3
(0.44 mL, 3.4 mmol) in anhydrous dichloromethane (10 mL)
was added AlCl3 (0.09 g, 0.68 mmol) at 0 °C. The reaction
mixture was stirred at 0 °C under a nitrogen atmosphere for
10 min. When the starting material disappeared (TLC), the
reaction mixture was quenched by the addition of aqueous
NaHCO3. The reaction mixture was partitioned between
dichloromethane and aqueous layers in a separating funnel.
The dichloromethane layer was washed with brine, dried over
Na2SO4 and evaporated under reduced pressure. The crude
product thus obtained was purified by flash column chromato-
graphy using 25% ethyl acetate in petroleum ether as the
eluent to obtain triacetate azide 6 (0.495 g, 99%) as a colour-
less gum. 1H NMR (500 MHz, CDCl3) δ: 1.79 (s, 6H, 2 ×
COCH3), 1.86 (s, 3H, COCH3), 3.22 (dd, J = 10.0, 4.0 Hz, 1H,
Fig. 4 Docking of 3-ﬂuorophenyl triazolophostin with IBC showing
preferred binding mode and the important cation–π and ﬂuorine–
oxygen interactions with residues Arg504 and Asp566, respectively. The
cation–π distance r = 2.97 Å. The ﬂuorophenyl moiety orients perpen-
dicular to the triazole ring. Color code for ligands: carbon, gray; oxygen,
red; nitrogen, blue; phosphorus, yellow; ﬂuorine, cyan.
Fig. 3 Concentration-dependent release of Ca2+ (%) by IP3, AdA and
triazolophostins from the intracellular stores of cells expressing IP3R1.
Results show means ± SEM from at least 3 experiments.
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H-6A′), 3.26 (dd, J = 10.0, 2.0 Hz, 1H, H-6B′), 3.46 (dd, J = 10.0,
3.4 Hz, 1H, H-2′), 3.52 (dd, J = 11.0, 4.0 Hz, 1H, H-5A), 3.61
(dd, J = 11.0, 3.0 Hz, 1H, H-5B), 3.77 (d, J = 9.8, Hz, 1H, H-5′),
4.22 (d, J = 12.0, Hz, 1H, 0.5 × PhCH2), 4.29–4.30 (m, 1H, H-4),
4.38–4.43 (m, 3H, 1.5 × PhCH2), 4.46–4.54 (m, 3H, H-3 and 1 ×
PhCH2), 4.88 (d, J = 3.3 Hz, 1H, H-1′), 4.95 (t, J = 9.8 Hz, 1H,
H-4′), 5.02 (d, J = 2.6 Hz, 1H, H-2), 5.27–5.29 (m, 2H, H-1 and
H-3′), 7.16–7.22 (m, 15H, 3 × Ph); 13C NMR (125 MHz, CDCl3)
δ: 20.5, 20.7, 20.9 (COCH3), 67.6 (C-6′), 69.0 (C-4′ and C-5′),
69.5 (C-5), 71.9 (C-3′), 73.3, 73.5, 73.5 (3 × CH2Ph), 73.9 (C-2),
74.5 (C-3), 76.6 (C-2′), 81.4 (C-4), 92.77 (C-1), 96.7 (C-1′), 127.5,
127.7, 127.7, 127.8, 128.0, 128.4, 128.4, 128.5 (Ar-C), 137.5,
137.7, 137.9 (ipso Ar–C), 169.8, 170.5, 170.5 (3 × COCH3); Anal.
calcd for C38H43N3O12: C, 62.20; H, 5.91; N, 5.73. found:
C, 62.12; H, 6.09; N, 5.71.
4. Synthesis of 2′,5,6′-tri-O-benzyl-3-O-α-D-glucopyranosyl-β-D-
ribofuranosyl azide (7)
To the suspension of triacetate 6 (0.42 g, 0.57 mmol) in MeOH
(10 mL) was added sodium methoxide (0.015 g, 0.28 mmol)
and stirred at room temperature. The reaction mixture became
clear after 30 min. When TLC showed complete disappearance
of the starting material, the reaction was quenched by adding
Dowex 50-ion exchange resin. The reaction mixture was then
filtered through a filter paper and washed successively with
methanol (2 times). The filtrate was concentrated under
reduced pressure to obtain a thick mass. The thick mass was
then purified by flash column chromatography using 50%
ethyl acetate in petroleum ether as the eluent to obtain triol
azide 7 (0.34 g, 96%) as a white solid. mp: 69–71 °C; 1H NMR
(500 MHz, CDCl3) δ: 3.33 (dd, J = 9.5, 3.5 Hz, 1H, H-2′),
3.43–3.54 (m, 5H, H-4′, H-5A, H-5B, H-6A′, H-6B′), 3.66 (ddd, J =
9.8, 8.7, 3.9, 1H, H-5′), 3.82–3.85 (m, 2H, H-3′ and H-2),
4.16–4.18 (m, 2H, 3-H and H-4), 4.38–4.48 (m, 4H, 2 × CH2Ph),
4.61–4.70 (m, 3H, H-1′ and 1 × CH2Ph), 5.20 (d, J = 1.4 Hz, 1H,
H-1), 7.18–7.29 (m, 15H, 3 × Ar-H); 13C NMR (125 MHz, CDCl3)
δ: 69.2 (C-5 or C-6′), 70.2 (C-5 or C-6′), 70.6 (C-5′), 71.1 (C-4′),
73.3 (C-3′), 73.5 and 73.6 (2 × CH2Ph), 74.0 (C-2), 74.3 (1 ×
CH2Ph), 78.3 (C-3 or C-4), 78.4 (C-2′), 81.4 (C-3 or C-4), 95.1
(C-1), 98.0 (C-1′), 127.6, 127.7, 127.8, 127.9, 128.4, 128.5, 128.6,
128.8 (Ar-C), 137.1, 137.6, 137.9 (ipso Ar-C); Anal. calcd for
C32H37N3O9: C, 63.25; H, 6.14; N, 6.92; found: C, 63.23;
H, 6.16; N, 6.90.
5. Synthesis of 2′,5,6′-tri-O-benzyl-2,3′,4′-tris-
(dibenzyloxyphosphoryl)-3-O-α-D-glucopyranosyl-β-D-
ribofuranosyl azide (8)
A solution of the triol 7 (0.1 g, 0.16 mmol), bis(benzyloxy) N,N-
diisopropylaminophosphine (0.27 mL, 0.82 mmol), and imida-
zolium triflate (0.20 g, 0.90 mmol) in anhydrous DCM (10 mL)
was stirred at room temperature under a N2 atmosphere for
30 min. The reaction mixture was then cooled to −78 °C, and
then m-CPBA (0.093 g, 0.54 mmol) was added. The reaction
mixture was then stirred for 45 min at −78 °C and then at
room temperature for an additional 30 min. The reaction was
quenched by the addition of aqueous NaHCO3. The reaction
mixture was partitioned between DCM and the aqueous layer
in a separating funnel. The DCM layer was washed with brine,
dried over Na2SO4 and evaporated under reduced pressure.
The crude product thus obtained was purified by flash column
chromatography using 25% acetone in petroleum ether as the
eluent to obtain pure 8 (0.206 g, 90%) as a colourless gum: 1H
NMR (500 MHz, CDCl3) δ: 3.43–3.58 (m, 5H, H-6A′, H-6B′, H-5B,
H-5A, H-2′), 3.70–3.72 (m, 1H, H-5′), 4.17–4.22 (m, 2H, H-4, and
0.5 × PhCH2), 4.27–4.34 (m, 3H, H-3 and 1 × PhCH2), 4.37–4.42
(m, 2H, 1 × PhCH2), 4.47 (dd, 19.05, 9.75 Hz, 1H, H-4′),
4.55–4.59 (m, 2H, H-2, 0.5 × PhCH2), 4.65 (dd, 11.95, 8.5 Hz,
1H, 0.5 × PhCH2), 4.78–4.94 (m, 12H, H-3′ and 5.5 × PhCH2),
5.01 (d, 3.55 Hz, 1H, H-1′), 5.30 (d, 2.6 Hz, 1H, H-1), 6.96–7.25
(m, 45H, 9 × Ph), 13C NMR (125 MHz, CDCl3) δ: 68.1 (C-6′),
69.1 (C-5), 69.3, 69.3, 69.4, 69.5, 69.8, 69.83, 69.9, (31P coupled,
PhCH2OP), 70.0 (C-5′), 72.0 (1 × PhCH2OC), 73.2 (C-3), 73.3,
73.5 (2 × PhCH2OC), 74.4 (
31P coupled, C-4′), 76.9 (C-2′), 77.6
(C-3′, 31P coupled), 78.1 (C-2, 31P coupled), 81.3 (C-4), 92.4
(C-1), 95.2 (C-1′), 127.6, 127.65, 127.70, 127.8, 128.06, 128.08,
128.26, 128.28, 128.31, 128.34, 128.39, 128.44, 128.49, 128.52,
128.62, 128.64, 128.68, 128.69 (aromatic carbons), 135.40,
135.45, 135.70, 135.77, 135.85, 135.90, 136.14, 136.16, 136.20,
136.23, 137.6, 137.9, 138.1, (31P coupled, ipso carbons of
POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.20, −1.90,
−2.15; Anal. calcd for C74H76N3O18P3: C, 64.02; H, 5.52;
N, 3.03. Found: C, 64.33; H, 5.45; N, 3.19.
6. Synthesis of fully protected triazolophostins
(a) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-1,2,3-triazole (9a). A mixture
of tris-phosphate 8 (0.1 g, 0.07 mmol), trimethylsilylacetylene
(0.011 mL, 0.071 mmol), Cu (0.018 g, 0.28 mmol) and CuSO4
(0.004 g, 0.014 mmol) in H2O–
tBuOH (1/1, v/v, 1 mL) was
stirred at room temperature for 12 h. After complete consump-
tion of the starting material (TLC, 12 h), TBAF (1.0 M in THF,
0.5 mL) was added to the reaction and the mixture was stirred
for additional 2 h at room temperature. The reaction mixture
was then filtered and washed with ethyl acetate. The filtrate
was extracted with ethyl acetate (2 × 10 mL) and washed with
water and brine. The organic layer was dried over MgSO4 and
concentrated under reduced pressure. The crude product thus
obtained was purified by flash column chromatography using
a mixture of acetone and petroleum ether (3 : 7 v/v) as the
eluent to obtain pure 9a (0.098 g, 97%) as a colourless gum.
1H NMR (500 MHz, CDCl3) δ: 3.43–3.45 (m, 1H, H-5A′),
3.47–3.57 (m, 3H, H-2″, H-5B′, H-6A″), 3.59–3.61 (m, 1H, H-6B″),
3.75 (ddd, J = 9.2, 4.65, 4.2 Hz, 1H, H-5″), 4.21–4.23 (m, 1H,
0.5 × PhCH2), 4.29–4.32 (m, 4H, H-4′, 1.5 × PhCH2), 4.39–4.46
(m, 3H, H-3′, H-4″ and 0.5 × PhCH2), 4.58–4.66 (m, 3H, 1.5 ×
PhCH2), 4.68–4.72 (m, 3H, 1.5 × PhCH2), 4.80–4.96 (m, 8H,
H-3″, 3.5 × PhCH2), 5.13 (d, J = 3.0 Hz, 1H, H-1″), 5.27 (ddd, J =
8.75, 8.2, 4.6 Hz, 1H, H-2′), 6.31 (d, 4.9 Hz, 1H, H-1′), 6.99–7.27
(m, 45H, 9 × C6H5), 7.48 (s, 1H, H-5), 7.61 (s, 1H, H-4);
13C
NMR (125 MHz, CDCl3) δ: 68.5 (C-6″), 69.1 (C-5′), 69.2, 69.36,
69.40, 69.5, 69.6, 69.8, 69.83, 69.9, 70.0, 70.02 (31P coupled,
Organic & Biomolecular Chemistry Paper
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PhCH2OP), 70.3 (C-5″), 71.9, 73.4, 73.6 (3 × PhCH2OC), 73.9
(C-3′), 74.5 (31P coupled, C-4″), 76.9 (C-2′), 78.0 (C-3″, 31P
coupled), 78.6 (C-2′, 31P coupled), 82.81 (C-4′), 90.0 (C-1′), 95.6
(C-1″), 122.4 (C-5), 127.6, 127.7, 127.74, 127.77, 127.8, 127.9,
128.0, 128.07, 128.1, 128.2, 128.3, 128.34, 128.4, 128.5, 128.52,
128.55, 128.59, 128.7, (aromatic carbons), 135.2, 135.28, 135.7,
135.74, 135.8, 135.87, 136.1, 136.2, 137.4, 137.6, 138.0 (31P
coupled, ipso carbons of POCH2Ph);
31P NMR (202.4 MHz,
CDCl3) δ: −1.427, −1.908, −2.128; Anal. calcd for
C76H78N3O18P3: C, 64.54; H, 5.56; N, 2.97. Found: C, 64.31; H,
5.42; N, 3.01.
(b) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(1-methylimidazol-5-yl)-1,2,3-
triazole (9b). A mixture of tris-phosphate 8 (0.2 g, 0.14 mmol),
5-ethynyl-1-methyl-1H-imidazole (0.016 mL, 0.15 mmol), Cu
(0.036 g, 0.57 mmol) and CuSO4 (0.008 g, 0.028 mmol) in
H2O–
tBuOH (1/1, v/v, 2 mL) was stirred at room temperature
for 12 h. After completion of the reaction, the mixture was fil-
tered and washed successively with ethyl acetate. The filtrate
was extracted with ethyl acetate and washed with water and
brine. The organic layer was dried over MgSO4 and concen-
trated under reduced pressure. The resulting crude product
was purified by flash column chromatography using a mixture
of acetone, diethyl ether and petroleum ether (4 : 1 : 15 v/v/v) as
the eluent to obtain pure 9b (0.205 g, 95%) as a colourless
gum. 1H NMR (500 MHz, CDCl3) δ: 3.55–3.76 (m, 8H, 1 ×
N-CH3, 6A″, H-6B″, H-5B′, H-2″ and H-5A′), 3.88 (bs, 1H, H-5″),
4.31–4.45 (m, 5H, H-4′ and 2 × PhCH2), 4.51–4.54 (m, 3H, H-4″
and 1 × PhCH2), 4.70–4.82 (m, 6H, H-3′, and 2.5 × PhCH2),
4.94–5.03 (m, 8H, H-3″ and 3.5 × PhCH2), 5.26 (bs, 1H, H-1″),
5.41 (bs, 1H, H-2′), 6.42 (s, 1H, H-1′), 6.97–7.34 (m, 47H, Ar-H),
7.75 (s, 1H, H-5); 13C NMR (125 MHz, CDCl3) δ: 33.4 (N-CH3),
68.6 (C-6″), 69.2 (C-5′), 69.4, 69.42, 69.5, 69.59, 69.8, 69.9, 70.03
(31P coupled PhCH2OP), 70.3 (C-5″), 71.92, 73.4, 73.7 (3 ×
PhCH2OC), 74.3 (C-3′), 74.5 (C-4″,
31P coupled), 77.0 (C-2′, 31P
coupled), 78.0 (C-2″), 78.8 (C-3″, 31P coupled), 83.1 (C-4′), 90.4
(C-1′, 31P coupled), 95.77 (C-1″), 119.41 (C-5), 127.64, 127.67,
127.71, 127.80, 127.8, 127.96, 128.0, 128.1, 128.14, 128.3,
128.5, 128.52, 128.6, 128.67 (aromatic carbons), 135.1, 135.2,
135.6, 135.76, 135.80, 135.9, 136.1, 136.18, 137.2, 137.6 (31P
coupled, ipso carbons of POCH2Ph), 138.0, 138.8 (ipso carbons
of COCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.453, −1.894,
−2.080; Anal. calcd for C80H82N5O18P3: C, 64.29; H, 5.53; N,
4.69. Found: C, 63.99; H, 5.23; N, 4.81.
(c) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-phenyl-1,2,3-triazole (9c).
A mixture of tris-phosphate 8 (0.1 g, 0.07 mmol), phenyl-
acetylene (0.016 mL, 0.158 mmol), Cu (0.018 g, 0.28 mmol)
and CuSO4 (0.004 g, 0.014 mmol) in H2O–
tBuOH (1/1, v/v,
1 mL) was stirred at rt for 12 h. After completion of the reac-
tion (TLC) the mixture was filtered. The filtrate was extracted
with ethyl acetate and washed successively with water and
brine. The organic layer was dried over MgSO4 and con-
centrated under reduced pressure. The crude product thus
obtained was purified by flash column chromatography using
a mixture of acetone and petroleum ether (3 : 7 v/v) as the
eluent to obtain pure 9c (0.101 g, 94%) as a colourless gum. 1H
NMR (500 MHz, CDCl3) δ: 3.46–3.52 (m, 2H, H-2″ and H-5A′),
3.55–3.58 (m, 2H, H-6B″ and H-5B′), 3.64–3.66 (m, 1H, H-6A″),
3.77–3.80 (m, 1H, H-5″), 4.21–4.35 (m, 5H, H-4′ and 2 ×
PhCH2), 4.41–4.46 (m, 3H, H-3′, H-4″ and 0.5 × PhCH2),
4.58–4.64 (m, 3H, 1.5 × PhCH2), 4.68–4.72 (m, 3H, 1.5 ×
PhCH2), 4.81–4.94 (m, 8H, H-3″, and 3.5 × PhCH2), 5.16 (d, J =
3.5 Hz, 1H, H-1″), 5.33 (ddd, J = 9.4, 8.55, 5.0, Hz, 1H, H-2′),
6.33 (d, 5.4 Hz, 1H, H-1′), 6.99–7.47 (m, 50H, 10 × C6H5), 7.83
(s, 1H, H-5); 13C NMR (125 MHz, CDCl3) δ: 68.7 (C-6″), 69.2
(C-5′), 69.2, 69.4, 69.45, 69.5, 69.55, 69.6, 69.85, 69.88, 70.0,
70.02, 70.1 (31P coupled, PhCH2OP), 70.4 (C-5″), 72.0, 73.5,
73.7 (3 × PhCH2OC), 74.5 (C-3′), 74.6 (
31P coupled, C-4″), 77.0
(31P coupled, C-2″), 78.1 (C-3″, 31P coupled), 78.8 (C-2′), 83.0
(C-4′), 90.1 (C-1′), 95.9 (C-1″), 118.2 (C-5), 125.8 (Ar-C), 127.6,
127.7, 127.8, 127.86, 128.0, 128.1, 128.2, 128.3, 128.4, 128.45,
128.50, 128.53, 128.6, 128.7 (aromatic carbons), 130.3, 135.2,
135.23, 135.3, 135.7, 135.8, 135.87, 135.93, 136.2, 136.25,
137.4, 137.6, 138.1, 148.1; (31P coupled, ipso carbons of
POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.551, −1.932,
−2.105; Anal. calcd for C82H82N3O18P3: C, 66.08; H, 5.55;
N, 2.82. Found: C, 65.95; H, 5.72; N, 2.97.
(d) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(2-pyridyl)-1,2,3-triazole (9d).
A mixture of tris-phosphate 8 (0.2 g, 0.14 mmol), 2-ethynylpyri-
dine (0.016 mL, 0.15 mmol), Cu (0.036 g, 0.57 mmol) and
CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH (1/1, v/v, 2 mL)
was stirred at rt for 12 h. After completion of the reaction
(TLC) the mixture was filtered. The filtrate was extracted with
ethyl acetate and washed successively with water and brine.
The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The crude product thus obtained was
purified by flash column chromatography using a mixture of
acetone and petroleum ether (3 : 7 v/v) as the eluent to obtain
pure 9d (0.104 g, 48%) as a colourless gum. 1H NMR
(500 MHz, CDCl3) δ: 3.43–3.45 (m, 1H, H-5A′), 3.48–3.59 (m,
4H, H-2″, H-5B′, H-6B″and H-6A″), 3.64–3.71–3.76 (m, 1H,
H-5″), 4.20–4.23 (m, 1H, 0.5 × PhCH2), 4.27–4.37 (m, 4H, H-4′
and 1.5 × PhCH2), 4.41–4.45 (m, 3H, H-3′, H-4″ and 0.5 ×
PhCH2), 4.60–4.62 (m, 1H, 0.5 × PhCH2), 4.66–4.72 (m, 5H, 2.5
× PhCH2), 4.80–4.93 (m, 8H, H-3″, and 3.5 × PhCH2), 5.15 (d,
J = 2.9 Hz, 1H, H-1″), 5.34–5.35 (m, 1H, H-2′), 6.30 (d, J =
5.0 Hz, 1H, H-1′), 6.99–7.19 (m, 45H, 9 × C6H5), 7.28 (d, J =
7.0 Hz, 1H, pyr-H), 7.72 (t, J = 7.0 Hz, 1H, pyr-H), 8.03 (d, J =
7.0 Hz, 1H, pyr-H), 8.44 (s, 1H, H-5), 8.52 (d, J = 4.0 Hz, 1H,
pyr-H); 13C NMR (125 MHz, CDCl3) δ: 68.4 (C-6″), 69.1 (C-5′),
69.13, 69.18, 69.4, 69.42, 69.5, 69.55, 69.8, 69.85, 69.87, 69.9,
70.0, 70.04 (31P coupled, PhCH2OP), 70.3 (C-5″), 72.0, 73.38,
73.6 (3 × PhCH2OC), 74.2 (C-3′), 74.5 (
31P coupled, C-4″), 77.1
(31P coupled, C-2″), 78.1 (C-3″, 31P coupled), 78.7 (C-2′), 83.1
(C-4′), 90.4 (C-1′), 95.7 (C-1″), 120.6 (C-5), 123.0 (Ar-C), 127.6,
127.7, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.43,
128.49, 128.5, 128.55 (aromatic carbons), 135.2, 135.25, 135.28,
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135.30, 136.19, 136.25, 137.37, 137.60, 138.11; (31P coupled,
ipso carbons of POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ:
−1.60, −1.95, −2.13; Anal. calcd for C81H81N4O18P3: C, 65.23;
H, 5.47; N, 3.76. Found: C, 65.01; H, 5.21; N, 3.92.
(e) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(2-fluorophenyl)-1,2,3-triazole
(9e). A mixture of tris-phosphate 8 (0.2 g, 0.14 mmol),
2-fluorophenyl acetylene (0.021 mL, 0.15 mmol), Cu (0.036 g,
0.57 mmol) and CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH
(1/1, v/v, 2 mL) was stirred at rt for 12 h. After completion of
the reaction (TLC) the mixture was filtered. The filtrate was
extracted with ethyl acetate and washed successively with water
and brine. The organic layer was dried over MgSO4 and con-
centrated under reduced pressure. The crude product thus
obtained was purified by flash column chromatography using
a mixture of acetone and petroleum ether (1 : 3 v/v) as the
eluent to obtain 9e (0.203 g, 93%) as a colourless gum. 1H
NMR (500 MHz, CDCl3) δ: 3.53–3.55 (m, 1H, H-5A′), 3.61–3.73
(m, 4H, H-2″, H-5B′, H-6A″ and H-6B″), 3.88 (bs, 1H, H-5″),
4.33–4.35 (m, 1H, 0.5 × PhCH2), 4.42–4.48 (m, 4H, H-4′ and 1.5
× PhCH2), 4.53–4.58 (m, 3H, H-3′, H-4″ and 0.5 × PhCH2),
4.72–4.81 (m, 6H, 3 × PhCH2), 4.96–5.06 (m, 8H, H-3″, 3.5 ×
PhCH2), 5.27 (bs, 1H, H-1″), 5.46 (bs, 1H, H-2′), 6.42 (bs, 1H,
H-1′), 7.13–7.40 (m, 48H, Ar-H), 8.21 (s, 1H, H-5), 8.30 (bs, 1H,
Ar-H); 13C NMR (125 MHz, CDCl3) δ: 68.4 (C-6″), 69.0 (C-5′),
69.1, 69.2, 69.4, 69.42, 69.5, 69.6, 69.8, 69.85, 69.89, 70.0, 70.05
(31P coupled, PhCH2OP), 70.2 (C-5″), 71.9, 73.4, 73.6 (3 ×
PhCH2OC), 74.2 (C-3′), 74.4 (
31P coupled, C-4″), 77.1 (31P
coupled, C-2″), 78.0 (C-3″, 31P coupled), 78.6 (C-2′), 83.0 (C-4′),
90.2 (C-1′), 95.7 (C-1″), 115.7 (C-5), 121.6, 121.7, 124.5,
124.6, 127.6, 127.9, 128.0, 128.1, 128.5, 128.6 (aromatic
carbons), 129.4, 129.5, 135.2, 135.22, 135.3, 135.7, 135.8,
135.84, 135.89, 136.2, 136.22, 137.3, 137.6, 138.1, 141.48,
141.5, 158.3, 160.3 (31P coupled, ipso carbons of POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.632, −1.930, −2.134; 19F
NMR (470.68 MHz, CDCl3) δ: −114.22; Anal. calcd for
C82H81FN3O18P3: C, 65.29; H, 5.41; N, 2.79. Found: C, 65.43;
H, 5.59; N, 2.67.
(f ) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(3-fluorophenyl)-1,2,3-triazole
(9f). A mixture of azide 8 (0.2 g, 0.14 mmol), 3-fluorophenyl
acetylene (0.021 mL, 0.15 mmol), Cu (0.036 g, 0.57 mmol) and
CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH (1/1, v/v, 2 mL)
was stirred at rt for 12 h. After completion of the reaction
(TLC), the mixture was filtered, the filtrate was extracted with
ethyl acetate and washed successively with water and brine.
The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The crude product thus obtained was
purified by flash column chromatography using a mixture of
acetone and petroleum ether (1 : 3 v/v) as the eluent to obtain
9f (0.188 g, 86%) as a colourless gum; 1H NMR (500 MHz,
CDCl3) δ: 3.58 (dd, J = 10.85, 2.45 Hz, 1H, H-5A′), 3.62 (dd, J =
9.65, 3.65 Hz, 1H, H-2″), 3.66–3.69 (m, 2H, H-6A″, H-5B′), 3.78
(dd, J = 10.8, 1.5 Hz, 1H, H-6B″) 3.90 (ddd, J = 10.8, 9.2, 4.2 Hz,
1H, H-5″), 4.33–4.38 (m, 2H, 1 × PhCH2), 4.41–4.44 (m, 2H, 1 ×
PhCH2), 4.46–4.47 (m, 1H, H-4′), 4.52–4.56 (m, 3H, H-3′, H-4″
and 0.5 × PhCH2), 4.70–4.75 (m, 3H, 1.5 × PhCH2), 4.80–4.84
(m, 3H, 1.5 × PhCH2), 4.92–5.06 (m, 8H, H-3″, 3.5 × PhCH2),
5.28 (d, J = 3.6 Hz, 1H, H-1″), 5.43 (ddd, J = 8.85, 5.2, 4.65 Hz,
1H, H-2′), 6.44 (d, 5.6 Hz, 1H, H-1′), 7.09–7.39 (m, 49H, Ar-H),
7.90 (s, 1H, H-5); 13C NMR (125 MHz, CDCl3) δ: 68.7 (C-6″),
69.1 (C-5′), 69.4, 69.5, 69.8, 69.6, 69.7, 69.87, 69.9, 69.94, 70.07,
70.1 (31P coupled, PhCH2OP), 72.0 (C-5″), 72.1, 73.5, 73.7 (3 ×
PhCH2OC), 74.5 (C-3′), 74.53 (
31P coupled, C-4″), 77.1 (31P
coupled, C-2″), 78.1 (C-3″, 31P coupled), 78.9 (C-2′), 83.1 (C-4′),
90.3 (C-1′), 95.9 (C-1″), 112.7, 114.8 (Ar-C), 118.5 (C-5), 121.4
(Ar-C), 127.6, 127.7, 127.8, 127.83, 127.9, 128.0, 128.07, 128.14,
128.31, 128.34, 128.43, 128.48, 128.5, 128.51, 128.69 (aromatic
carbons), 130.2, 130.27, 136.2, 136.23, 137.31, 137.61, 138.1,
148.1, 162.3, 164.2 (31P coupled, ipso carbons of POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.515, −1.920, −2.064; 19F
NMR (470.68 MHz, CDCl3) δ: −112.766; Anal. calcd for
C82H81FN3O18P3: C, 65.29; H, 5.41; N, 2.79. Found: C, 65.50;
H, 5.21; N, 2.66.
(g) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(4-fluorophenyl)-1,2,3-triazole
(9g). A mixture of azide 8 (0.2 g, 0.14 mmol), 4-fluorophenyl
acetylene (0.018 mL, 0.15 mmol), Cu (0.036 g, 0.57 mmol) and
CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH (1/1, v/v, 2 mL)
was stirred at rt for 12 h. After completion of the reaction
(TLC), the mixture was filtered, the filtrate was extracted with
ethyl acetate and washed successively with water and brine.
The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The resulting crude product thus
obtained was purified by flash column chromatography using
a mixture of 25% acetone in petroleum ether as the eluent to
obtain pure 9g (0.207 g, 95%) as a colourless gum; 1H NMR
(500 MHz, CDCl3) δ: 3.47–3.52 (m, 2H, H-2″ and H-5A′),
3.55–3.59 (m, 2H, H-6A″, H-5B′), 3.65–3.67 (m, 1H, H-6B″),
3.77–3.80 (m, 1H, H-5″), 4.21–4.28 (m, 2H, 1 × PhCH2),
4.30–4.35 (m, 3H, H-4′), 4.39–4.45 (m, 3H, H-4″ and 1 ×
PhCH2), 4.61–4.65 (m, 3H, H-3′, and 1 × PhCH2), 4.67–4.73 (m,
3H, 1.5 × PhCH2), 4.81–4.97 (m, 8H, H-3″, 3.5 × PhCH2), 5.16
(d, J = 3.6 Hz, 1H, H-1″), 5.32 (ddd, J = 9.2, 8.5, 5.0 Hz, 1H,
H-2′), 6.34 (d, 5.6 Hz, 1H, H-1′), 6.94–7.37 (m, 49H, Ar-H), 7.79
(s, 1H, H-5); 13C NMR (125 MHz, CDCl3) δ: 68.6 (C-6″), 69.2
(C-5′), 69.22, 69.4, 69.45, 69.5, 69.56, 69.6, 69.8, 69.9, 69.91,
70.03, 70.07 (31P coupled, PhCH2OP), 70.3 (C-5″), 72.0, 73.5,
73.7 (3 × PhCH2OC), 74.4 (C-3′), 74.5 (
31P coupled, C-4″), 77.3
(31P coupled, C-2″), 78.0 (C-3″, 31P coupled), 78.9 (C-2′), 83.0
(C-4′), 90.2 (C-1′), 95.9 (C-1″), 115.6 (C-5), 117.9, 127.5, 127.51,
127.62, 127.67, 127.7, 127.8, 127.87, 128.0, 128.01, 128.07,
128.1, 128.16, 128.20, 128.35, 128.39, 128.47, 128.5, 128.55,
128.65, 128.67 (aromatic carbons), 136.14, 136.20, 137.4, 137.6,
138.0, 147.5, 162.1, 164.4 (31P coupled, ipso carbons of
POCH2Ph);
31P NMR (202.4 MHz, CDCl3) δ: −1.49, −1.920,
−2.092; 19F NMR (470.68 MHz, CDCl3) δ: −113.585; Anal. calcd
for C82H81FN3O18P3: C, 65.29; H, 5.41; N, 2.79. Found:
C, 64.98; H, 5.11; N, 2.93.
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(h) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(3,5-difluorophenyl)-1,2,3-
triazole (9h). A mixture of azide 8 (0.2 g, 0.14 mmol), 3,5-
difluorophenyl acetylene (0.018 mL, 0.15 mmol), Cu (0.036 g,
0.57 mmol) and CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH
(1/1, v/v, 2 mL) was stirred at rt for 12 h. After completion of
the reaction (TLC), the mixture was filtered. The filtrate was
extracted with ethyl acetate and washed successively with water
and brine. The organic layer was dried over MgSO4 and con-
centrated under reduced pressure. The crude product thus
obtained was purified by flash column chromatography using
a mixture of 25% acetone in petroleum ether as the eluent to
obtain pure 9h (0.2 g, 91%) as a colourless gum. 1H NMR
(500 MHz, CDCl3) δ: 3.46 (dd, J = 10.8, 2.1 Hz, 1H, H-5A′), 3.51
(dd, J = 9.65, 3.6 Hz, 1H, H-2″), 3.54–3.58 (m, 2H, H-6A″ and
H-5B′), 3.68 (dd, J = 10.7, 1.3 Hz, 1H, H-6B″), 3.79 (ddd, J = 5.95,
4.85, 3.95 Hz, 1H, H-5″), 4.24 (dd, J = 11.5, 7.5 Hz, 2H, 1 ×
PhCH2), 4.29–4.34 (m, 2H, 1 × PhCH2), 4.36 (d, J = 2.3 Hz, 1H,
H-4′), 4.38–4.45 (m, 3H, H-3′, H-4″ and 0.5 × PhCH2), 4.59–4.62
(m, 3H, 1.5 × PhCH2), 4.68–4.72 (m, 3H, 1.5 × PhCH2),
4.81–4.94 (m, 8H, H-3″, 3.5 × PhCH2), 5.18 (d, J = 3.6 Hz, 1H,
H-1″), 5.31 (ddd, J = 8.85, 5.2, 4.65 Hz, 1H, H-2′), 6.33 (d, J =
5.75 Hz, 1H, H-1′), 6.97–7.29 (m, 48H, Ar-H), 7.77 (s, 1H, H-5);
13C NMR (125 MHz, CDCl3) δ: 68.7 (C-6″), 69.2 (C-5′), 69.23,
69.4, 69.45, 69.5, 69.57, 69.6, 69.8, 69.85, 69.9, 70.02, 70.07
(31P coupled, PhCH2OP), 70.4 (C-5″), 72.0, 73.48, 73.7 (3 ×
PhCH2OC), 74.5 (C-3′), 74.54 (
31P coupled, C-4″), 77.1 (31P
coupled, C-2″), 78.0 (C-3″, 31P coupled), 78.9 (C-2′), 83.3 (C-4′),
90.4 (C-1′), 95.8 (C-1″), 108.7 (C-5), 118.9,127.6, 127.7, 127.73,
127.85, 127.92, 128.0, 128.1, 128.14, 128.3, 128.35, 128.39,
128.5, 128.51, 128.54, 128.58, 128.66, 128.79 (aromatic
carbons), 135.2, 135.23, 135.25, 135.7, 135.71, 135.8, 135.89,
136.1, 136.2, 137.2, 137.23, 137.6, 146.45, 162.5, 163.3 (31P
coupled, ipso carbons of POCH2Ph);
31P NMR (202.4 MHz,
CDCl3) δ: −1.502, −1.902, −2.068; 19F NMR (470.68 MHz,
CDCl3) δ: −109.331; Anal. calcd for C82H80F2N3O18P3: C, 64.52;
H, 5.28; N, 2.75. Found: C, 64.37; H, 5.58; N, 2.91.
(i) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(4-methoxyphenyl)-1,2,3-triazole
(9i). A mixture of azide 8 (0.2 g, 0.14 mmol), 4-methoxyphenyl
acetylene (0.02 mL, 0.15 mmol), Cu (0.036 g, 0.57 mmol) and
CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH (1/1, v/v, 2 mL)
was stirred at rt for 12 h. After completion of the reaction
(TLC) the mixture was filtered. The filtrate was extracted with
ethyl acetate and washed successively with water and brine.
The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The crude product thus obtained was
purified by flash column chromatography using a mixture of
acetone and petroleum ether (1 : 3 v/v) as the eluent to obtain
9i (0.193 g, 88%) as a colourless gum; 1H NMR (500 MHz,
CDCl3) δ: 3.49–3.56 (m, 5H, 6A″, H-6B″, H-5B′, H-2″ and H-5A′),
3.77 (bs, 4H, 1 × OCH3 and H-5″), 4.21–4.35 (m, 5H, H-4′ and
2 × PhCH2), 4.40–4.45 (m, 3H, H-3′, H-4″ and 0.5 × PhCH2),
4.58–4.72 (m, 6H, and 3 × PhCH2), 4.84–4.93 (m, 8H, H-3″ and
3.5 × PhCH2), 5.16 (bs, 1H, H-1″), 5.32 (bs, 1H, H-2′), 6.33 (d, J
= 3.2 Hz, 1H, H-1′), 6.80 (d, J = 7.5 Hz, 2H, Ar-H), 7.00–7.28 (m,
45H, 9 × C6H5), 6.38 (d, J = 7.5 Hz, 2H, Ar-H), 7.75 (s, 1H, H-5);
13C NMR (125 MHz, CDCl3) δ: 55.4 (OCH3), 68.6 (C-6″), 69.16
(C-5′), 69.2, 69.4, 69.44, 69.5, 69.58, 69.85, 69.9, 70.07, (31P
coupled PhCH2OP), 70.3 (C-5″), 72.0, 73.4, 73.6 (3 ×
PhCH2OC), 74.4 (C-3′ and C-4″,
31P coupled), 77.0 (C-2′, 31P
coupled), 78.0 (C-2″), 78.6 (C-3″, 31P coupled), 83.0 (C-4′), 90.3
(C-1′, 31P coupled), 95.9 (C-1″), 114.2, 117.5 (C-5), 127.1, 127.2,
127.6, 127.7, 127.8, 127.82, 127.85, 128.0, 128.03, 128.07,
128.1, 128.2, 128.3, 128.4, 128.45, 128.5, 128.52, 128.6, 128.64
(aromatic carbons), 135.1, 135.15, 135.2, 135.65, 135.70, 135.8,
135.84, 136.1, 136.16, 137.4, 137.6, (31P coupled, ipso carbons
of POCH2Ph), 138.0 (ipso carbons of COCH2Ph);
31P NMR
(202.4 MHz, CDCl3) δ: −1.576, −1.941, −2.118; Anal. calcd for
C83H84N3O19P3: C, 65.56; H, 5.57; N, 2.76. Found: C, 65.66;
H, 5.77; N, 2.95.
( j) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(2-formylphenyl)-1,2,3-triazole
(9j). A mixture of azide 8 (0.2 g, 0.14 mmol), 2-ethynylbenz-
aldehyde (0.02 g, 0.15 mmol), Cu (0.036 g, 0.57 mmol) and
CuSO4 (0.008 g, 0.028 mmol) in H2O–
tBuOH (1/1, v/v, 2 mL)
was stirred at rt for 12 h. After completion of the reaction
(TLC) the mixture was filtered. The filtrate was extracted with
ethyl acetate and washed successively with water and brine.
The organic layer was dried over MgSO4 and concentrated
under reduced pressure. The crude product thus obtained was
purified by flash column chromatography using a mixture of
acetone and petroleum ether (1 : 3 v/v) as the eluent to obtain
pure 9j (0.19 g, 87%) as a colourless gum;. 1H NMR (500 MHz,
CDCl3) δ: 3.57–3.64 (m, 2H, H-2″ and H-5A′), 3.68–3.70 (m, 2H,
H-5B′ and H-6A″), 3.76–3.78 (m, 1H, H-6B″), 3.90 (bs, 1H, H-5″),
4.33–4.44 (m, 4H, 2 × PhCH2), 4.49–4.58 (m, 4H, H-4′, H-4″ and
1 × PhCH2), 4.72–4.86 (m, 6H, H-3′ and 2.5 × PhCH2),
4.93–5.07 (m, 8H, H-3″, 3.5 × PhCH2), 5.29 (bs, 1H, H-1″), 5.47
(bs, 1H, H-2′), 6.48 (d, 5.0 Hz, 1H, H-1′), 7.13–7.41 (m, 46H,
Ar-H), 7.51–7.59 (m, 2H, Ar-H), 8.00 (s, 1H, H-5), 8.05 (d, J = 7.4
Hz, 1H, Ar-H), 10.35 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3)
δ: 68.6 (C-6″), 68.66 (C-5′), 69.2, 69.22, 69.3, 69.4, 69.45, 69.6,
69.61, 69.87, 69.9, 69.94, 70.07, 70.1 (31P coupled, PhCH2OP),
70.4 (C-5″), 72.0, 73.5, 73.7 (3 × PhCH2OC), 74.3 (C-3′), 74.5
(31P coupled, C-4″), 77.3 (31P coupled, C-2″), 78.0 (C-3″, 31P
coupled), 78.9 (C-2′), 83.2 (C-4′), 90.5 (C-1′), 95.8 (C-1″), 121.7
(C-5), 127.7, 127.71, 127.73, 127.8, 127.83, 127.86, 128.0, 128.1,
128.14, 128.19, 128.35, 128.38, 128.5, 128.54, 128.59, 128.69
(aromatic carbons), 129.9, 132.8, 134.1, 136.2, 137.2, 137.6,
138.1, 145.6 (31P coupled, ipso carbons of POCH2Ph), 192.21
(CHO); 31P NMR (202.4 MHz, CDCl3) δ: −1.32, −1.89, −2.07;
Anal. calcd for C83H82N3O19P3: C, 65.65; H, 5.44; N, 2.77.
Found: C, 65.41; H, 5.73; N, 2.90.
(k) Synthesis of 1-{5-O-benzyl-2-O-bisbenzyloxyphosphoryl-
3-O-[2,6-di-O-benzyl-3,4-di-O-(bisbenzyloxyphosphoryl)-α-D-glu-
copyranosyl]-β-D-ribofuranosyl}-4-(6-methoxynaphth-2-yl)-1,2,3-
triazole (9k). A mixture of azide 8 (0.1 g, 0.07 mmol),
2-ethynyl-6-methoxynaphthalene (0.014 g, 0.077 mmol), Cu
Paper Organic & Biomolecular Chemistry
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(0.018 g, 0.28 mmol) and CuSO4 (0.004 g, 0.014 mmol) in
H2O–
tBuOH (1/1, v/v, 1 mL) was stirred at rt for 12 h. After
completion of the reaction (TLC) the mixture was filtered. The
filtrate was extracted with ethyl acetate and washed succes-
sively with water and brine. The organic layer was dried over
MgSO4 and concentrated under reduced pressure. The crude
product thus obtained was purified by flash column chromato-
graphy using 25% acetone in petroleum ether as the eluent to
obtain pure, protected triazolophostin 9k (93 mg, 82%) as a
colourless gum; 1H NMR (500 MHz, CDCl3) δ: 3.47–3.52 (m,
2H, H-2″ and H-5A′), 3.55–3.59 (m, 2H, H-5B′ and H-6A″),
3.64–3.66 (m, 1H, H-6B″), 3.77–3.80 (m, 1H, H-5″), 3.85 (s, 3H,
OCH3), 4.21–4.24 (m, 1H, 0.5 × PhCH2), 4.28–4.36 (m, 4H, H-4′
and 1.5 × PhCH2), 4.41–4.48 (m, 3H, H-3′, H-4″ and 1 ×
PhCH2), 4.59–4.65 (m, 3H, 1.5 × PhCH2), 4.69–4.72 (m, 3H,
1.5 × PhCH2), 4.80–4.97 (m, 8H, H-3″, 3.5 × PhCH2), 5.18 (d, J =
3.3 Hz, 1H, H-1″), 5.37 (ddd, J = 9.1, 8.5, 4.9 Hz, 1H, H-2′), 6.35
(d, 5.3 Hz, 1H, H-1′), 7.00–7.19 (m, 45H, 9 × C6H5), 7.29 (d, J =
7.5 Hz, 2H, Ar-H), 7.48 (d, J = 7.5 Hz, 1H, Ar-H), 7.63 (t, J =
7.5 Hz, 2H, Ar-H), 7.89 (s, 1H, Ar-H), 8.05 (s, 1H, H-5); 13C
NMR (125 MHz, CDCl3) δ: 55.4 (OCH3), 68.7 (C-6″), 69.2 (C-5′),
69.4, 69.6, 69.8, 69.9, 70.1 (31P coupled, PhCH2OP), 70.3 (C-5″),
72.0, 73.5, 73.6 (3 × PhCH2OC), 74.5 (C-3′), 74.54 (
31P coupled,
C-4″), 77.0 (31P coupled, C-2″), 78.1 (C-3″, 31P coupled), 78.8
(C-2′), 83.1 (C-4′), 90.1 (C-1′), 95.9 (C-1″), 105.9, 119.20 (C-5),
124.5, 127.2, 127.6, 127.63, 127.7, 127.8, 127.86, 127.89,
127.97, 128.0, 128.1, 128.13, 128.2, 128.3, 128.36, 128.38,
128.45, 128.5, 128.52, 128.57, 128.6, 128.7, 129.0 (aromatic
carbons), 129.8, 134.4, 136.2, 137.2, 137.5, 137.6, 138.1 (31P
coupled, ipso carbons of POCH2Ph);
31P NMR (202.4 MHz,
CDCl3) δ: −1.524, −1.920, −2.082; Anal. calcd for
C87H86N3O19P3: C, 66.53; H, 5.52; N, 2.68. Found: C, 66.74; H,
5.39; N, 2.88.
7. General procedure for the synthesis of triazolophostins
To a solution of protected triazolophostins 9a–k (80–200 mg,
0.06–0.13 mmol) and cyclohexene (2 mL) in a mixture of
methanol and water (9 : 1 v/v, 5 mL), Pd(OH)2 (20% on carbon,
50 mg) was added and the mixture was stirred at 80 °C for 4 h.
The reaction mixture was then cooled, filtered through a mem-
brane filter by washing successively with methanol and water.
The combined filtrate was evaporated under reduced pressure.
The crude product thus obtained was purified by ion-exchange
column chromatography on a Q-Sepharose matrix using
0→1.0 M triethylammonium bicarbonate (TEAB) as the eluent
to obtain pure triazolophostins 10a–k.
(a) 3′-O-α-D-glucopyranosyl-1-β-D-ribofuranosyl-1,2,3-triazole
2′,3″,4″-trisphosphate [triazolophostin] (10a). By using 80 mg
(0.056 mmol) of 9a, 33 mg (97%) of triazolophostin 10a was
obtained as a white hygroscopic solid: 1H NMR (500 MHz,
D2O) δ: 3.74–3.80 (m, 7H, H-4″, H-5″, H-5A′, H-5B′, H-6A″, H-6B″
and H-2″), 4.03 (bs, 1H, H-4′), 4.41 (bs, 2H, H-3′ and H-3″),
5.14 (bs, 1H, H-2′), 5.23 (bs, 1H, H-1″), 6.38 (bs, 1H, H-1′), 7.80
(s, 1H, H-5), 8.18 (s, 1H, H-4); 13C NMR (125 MHz, D2O) δ: 60.3
(C-5′), 60.8 (C-6″), 70.9 (C-2″, 31P coupled), 71.8 (C-5″, 31P
coupled), 72.6 (C-4″, 31P coupled), 73.6 (C-3′, 31P coupled), 76.3
(C-2′, 31P coupled), 77.3 (C-3″, 31P coupled), 83.8 (C-4′), 90.8
(C-1′, 31P coupled), 98.0 (C-1″), 125.1 (C-4, C-5); 31P NMR
(202.4 MHz, CDCl3) δ: 3.496, 3.570, 4.382; HRMS (ESI) mass
calcd for C13H24N3O18P3 [M]
+, 603.0268, found: 603.0271.
(b) 4-(1-Methyl-imidazol-5-yl)-triazolophostin (10b). By
using 105 mg (0.07 mmol) of 9b, 45 mg (94%) of triazolophos-
tin 10b was obtained as a white hygroscopic solid: 1H NMR
(500 MHz, D2O) δ: 3.74–3.81 (m, 5H, H-2″, H-5A′, H-5B′, H-6A″
and H-6B″), 3.87 (dd, 1H, J = 12.8, 3.05 Hz, H-4″), 3.94 (s, 3H,
N-CH3), 4.08–4.10 (m, 1H, H-5″), 4.47–4.50 (m, 2H, H-4′ and
H-3″), 4.66–4.70 (m, 1H, obscured by HDO peaks, H-3′), 5.24
(dd, 1H, J = 8.8, 4.45 Hz, H-2′), 5.27 (d, J = 3. 3 Hz, 1H, H-1″),
6.46 (d, J = 3.9 Hz, 1H, H-1′), 7.76 (s, 1H, ImH-4), 8.63 (s, 1H,
H-5), 8.80 (s, 1H, ImH-2); 13C NMR (125 MHz, D2O) δ: 34.8
(N-CH3), 60.3 (C-5′), 60.7 (C-6″), 70.6 (C-2″,
31P coupled), 71.7
(C-5″, 31P coupled), 72.8 (C-4″, 31P coupled), 73.6 (C-3′, 31P
coupled), 76.5 (C-2′, 31P coupled), 77.7 (C-3″, 31P coupled), 84.2
(C-4′), 91.2 (C-1′, 31P coupled), 98.0 (C-1″), 118.8 (C-5), 124.8
(ImC-4), 125.0 (C-4), 134.1 (ImC-5), 136.4 (ImC-2); 31P NMR
(202.4 MHz, CDCl3) δ: 3.62, 3.69, 4.41; HRMS (ESI) mass calcd
for C17H28N5O18P3 [M + H]
+, 684.072, found 684.0699.
(c) 4-Phenyl triazolophostin (10c). By using 100 mg
(0.067 mmol) of 9c, 41 mg (91%) of triazolophostin 10c was
obtained as a white hygroscopic solid: 1H NMR (500 MHz,
D2O) δ: 3.73–3.85 (m, 6H, H-2″, H-5A′, H-4″, H-5B′, H-6A″,
H-6B″), 4.07–4.09 (m, 1H, H-5″), 4.43 (bs, 1H, H-4′), 4.47–4.49
(m, 1H, H-3″), 4.64–4.75 (m, 1H, H-3′), 5.19–5.20 (m, 1H, H-2′),
5.24 (s, 1H, H-1″), 6.39 (d, 1H, 3.65 Hz, H-1′), 7.38–7.41 (m, 1H,
Ar-H), 7.46 (t, J = 7.5 Hz, 2H, Ar-H), 7.78 (d, J = 7.5 Hz, 2H, Ar-
H), 8.48 (s, 1H, H-5); 13C NMR (125 MHz, D2O) δ: 60.2 (C-5′),
60.8 (C-6″), 70.4 (C-2″, 31P coupled), 71.6 (C-5″, 31P coupled),
73.0 (C-4″, 31P coupled), 73.8 (C-3′, 31P coupled), 76.6 (C-2′, 31P
coupled), 78.1 (C-3″, 31P coupled), 83.9 (C-4′), 91.0 (C-1′, 31P
coupled), 98.1 (C-1″), 121.3 (C-5), 125.9, 126.0, 129.1, 129.2,
129.3 (Ar-H); 31P NMR (202.4 MHz, D2O) δ: 3.551, 3.597, 4.343;
HRMS (ESI) mass calcd for C19H28N3O18P3 [M − H]+, 678.0503,
found 678.0482.
(d) 4-(2-Pyridyl)-triazolophostin (10d). By using 100 mg
(0.067 mmol) of 9d, 21.2 mg (47%) of triazolophostin 10d was
obtained as a sticky mass: 1H NMR (500 MHz, D2O) δ:
3.79–3.90 (m, 5H, H-6A″, H-6B″, H-5A′, H-5B′, H-2″), 4.11–4.12
(m, 1H, H-5″), 4.49–4.51 (m, 2H, H-4′ and H-4″), 4.72 (m, 2H,
obscured by HDO peaks, H-3′ and H-3″), 5.26–5.29 (m, 2H,
H-2′ and H-1″), 6.51 (s, 1H, H-1′), 7.98 (s, 1H, Pyr-H), 8.40 (d, J
= 6.5 Hz, 1H, Pyr-H), 8.62 (s, 1H, Pyr-H), 8.74 (s, 1H, Pyr-H),
9.04 (s, 1H, H-5); 13C NMR (125 MHz, D2O) δ: 60.3 (C-5′), 60.7
(C-6″), 70.6 (C-2″, 31P coupled), 71.8 (C-5″, 31P coupled), 73.0
(C-4″, 31P coupled), 73.8 (C-3′, 31P coupled), 76.7 (C-2′, 31P
coupled), 78.0 (C-3″, 31P coupled), 84.5 (C-4′), 91.4 (C-1′, 31P
coupled), 98.1 (C-1″), 124.9 (C-5), 126.2, 139.4, 141.3, 142.4,
147.6 (Ar-C); 31P NMR (202.4 MHz, D2O) δ: 3.637, 3.720, 4.448;
HRMS (ESI) mass calcd for C18H27N4O18P3 [M − H]+, 679.0455,
found 679.0431.
(e) 4-(2-Fluorophenyl)-triazolophostin (10e). By using
190 mg (0.12 mmol) of 9e, 79 mg (91%) of triazolophostin 10e
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
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MeOD) 3.58–3.81 (m, 6H, H-5″, H-6A″, H-6B″, H-5A′, H-5B′,
H-2″), 4.09–4.11 (m, 1H, H-4″), 4.30 (bs, 1H, H-4′), 4.51–4.53
(m, 1H, H-3″), 4.68 (t, J = 5.0 Hz, 1H, H-3′), 5.15 (bs, 1H, H-1″),
5.22 (bs, 1H, H-2′), 6.31 (bs, 1H, H-1′), 7.10–7.14 (m, 1H, Ar-H),
7.18 (t, J = 7.5 Hz, 1H, Ar-H), 7.28 (dd, J = 13.0, 6.5 Hz, 1H, Ar-
H), 8.02 (t, J = 7.5 Hz, 1H, Ar-H), 8.51 (s, 1H, H-5); 13C NMR
(125 MHz, MeOD) δ: 61.9 (C-5′), 62.1 (C-6″), 72.7 (C-2″, 31P
coupled), 73.6 (C-5″, 31P coupled), 74.6 (C-4″, 31P coupled),
76.8 (C-3′, 31P coupled), 79.1 (C-2′, 31P coupled), 79.5 (C-3″, 31P
coupled), 85.3 (C-4′), 93.0 (C-1′, 31P coupled), 100.6 (C-1″),
116.9 (C-5), 124.0, 125.8, 128.8, 131.1, 142.4, 159.8, 161.7 (Ar-
C); 31P NMR (202.4 MHz, MeOD) δ: 0.601 (2P), −0.550; 19F
NMR (470.68 MHz, MeOD) δ: −116.02; HRMS (ESI) mass calcd
for C19H27FN3O18P3 [M]
+, 697.0486, found 697.0490.
(f ) 4-(3-Fluorophenyl)-triazolophostin (10f). By using
180 mg (0.11 mmol) of 9f, 78 mg (93%) of triazolophostin 10f
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
MeOD) 3.61–3.62 (m, 1H, H-2″), 3.69–3.84 (m, 5H, H-5″, H-6A″,
H-6B″, H-5A′, H-5B′), 4.13–4.18 (m, 1H, H-4″), 4.32–4.33 (m, 1H,
H-4′), 4.53–4.55 (m, 1H, H-3″), 4.69 (t, J = 5.0 Hz, 1H, H-3′),
5.18 (d, J = 3.0 Hz, 1H, H-1″), 5.27 (t, J = 3.8 Hz, 1H, H-2′), 6.32
(d, J = 3.0 Hz, 1H, H-1′), 7.01 (dt, J = 8.5, 2.0 Hz, 1H, Ar-H), 7.38
(dd, J = 8.0, 14.0 Hz, 1H, Ar-H), 7.51 (d, J = 9.7 Hz, 1H, Ar-H),
7.57 (d, J = 7.5 Hz, 1H, Ar-H), 8.58 (s, 1H, H-5); 13C NMR
(125 MHz, MeOD) δ: 61.9 (C-5′), 62.0 (C-6″), 72.5 (C-2″, 31P
coupled), 73.4 (C-5″, 31P coupled), 75.2 (C-4″, 31P coupled),
76.6 (C-3′, 31P coupled), 79.3 (C-2′, 31P coupled), 80.0 (C-3″, 31P
coupled), 85.4 (C-4′), 92.7 (C-1′, 31P coupled), 100.5 (C-1″),
113.4 (C-5), 116.2, 121.8, 122.6, 132.0, 133.9, 148.0 (Ar-C); 31P
NMR (202.4 MHz, MeOD) δ: −0.755, −0.131, 0.279; 19F NMR
(470.68 MHz, MeOD) δ: −114.722; HRMS (ESI) mass calcd for
C19H27FN3O18P3 [M]
+, 697.0486, found 697.0472.
(g) 4-(4-Fluorophenyl)-triazolophostin (10g). By using
200 mg (0.13 mmol) of 9g, 88 mg (95%) of triazolophostin 10g
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
MeOD) 3.60–3.83 (m, 6H, H-2″, H-5″, H-6A″, H-6B″, H-5A′,
H-5B′), 4.13 (bs, 1H, H-4″), 4.31 (bs, 1H, H-4′), 4.54 (bs, 1H,
H-3″), 4.68 (bs, 1H, H-3′), 5.17 (bs, 1H, H-1″), 5.25 (bs, 1H,
H-2′), 6.30 (bs, 1H, H-1′), 7.09 (t, J = 8.5 Hz, 2H, Ar-H), 7.76 (d,
J = 5.5 Hz, 2H, Ar-H), 8.50 (s, 1H, H-5); 13C NMR (125 MHz,
MeOD) δ: 61.9 (C-5′), 62.1 (C-6″), 72.6 (C-2″, 31P coupled), 73.5
(C-5″, 31P coupled), 74.9 (C-4″, 31P coupled), 76.7 (C-3′, 31P
coupled), 79.1 (C-2′, 31P coupled), 79.7 (C-3″, 31P coupled), 85.4
(C-4′), 92.8 (C-1′, 31P coupled), 100.5 (C-1″), 116.8 (C-5), 116.9,
121.2, 128.0, 128.8, 128.9, 148.2, 163.3, 165.2 (Ar-C); 31P NMR
(202.4 MHz, MeOD) δ: −0.602, −0.269, 0.473; 19F NMR
(470.68 MHz, MeOD) δ: −115.406; HRMS (ESI) mass calcd for
C19H27FN3O18P3 [M]
+, 697.0486, found 697.0481.
(h) 4-(3,5-Difluorophenyl)-triazolophostin (10h). By using
200 mg (0.13 mmol) of 9h, 79 mg (84%) of triazolophostin 10h
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
MeOD) 3.59–3.79 (m, 6H, H-2″, H-5″, H-6A″, H-6B″, H-5A′,
H-5B′), 4.10 (bs, 1H, H-4″), 4.30 (bs, 1H, H-4′), 4.52 (bs, 1H,
H-3″), 4.66 (bs, 1H, H-3′), 5.15 (bs, 1H, H-1″), 5.22 (bs, 1H,
H-2′), 6.28 (s, 1H, H-1′), 6.83 (t, J = 8.9 Hz, 1H, Ar-H), 7.36 (d,
J = 6.2 Hz, 2H, Ar-H), 8.60 (s, 1H, H-5); 13C NMR (125 MHz,
MeOD) δ: 61.9 (C-5′), 62.1 (C-6″), 72.7 (C-2″, 31P coupled), 73.6
(C-5″, 31P coupled), 74.7 (C-4″, 31P coupled), 76.7 (C-3′, 31P
coupled), 79.0 (C-2′, 31P coupled), 79.5 (C-3″, 31P coupled), 85.4
(C-4′), 92.9 (C-1′, 31P coupled), 100.6 (C-1″), 104.2 (C-5), 109.3,
122.4, 135.2, 146.9, 163.9, 165.9 (Ar-C); 31P NMR (202.4 MHz,
MeOD) δ: −0.650, 0.47, 0.81; 19F NMR (470.68 MHz, MeOD) δ:
−111.10; HRMS (ESI) mass calcd for C19H26F2N3O18P3 [M]+,
715.0392, found 715.0402.
(i) 4-(4-Methoxyphenyl)-triazolophostin (10i). By using
195 mg (0.12 mmol) of 9i, 87 mg (96%) of triazolophostin 10i
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
D2O) δ: 3.65–3.76 (m, 9H, H-2″, H-5″, H-6A″, H-6B″, H-5A′, H-5B′
and 1 × OCH3), 4.00–4.02 (m, 1H, H-4″), 4.33 (bs, 1H, H-4′),
4.40–4.41 (m, 1H, H-3″), 4.54 (t, J = 5.1 Hz, 1H, H-3′), 5.08–5.15
(m, 1H, H-2′), 5.16 (bs, 1H, H-1″), 6.27 (d, J = 3.2 Hz, 1H, H-1′),
6.89 (d, J = 8.6 Hz, 1H, Ar-H), 7.54 (d, J = 8.6 Hz, 1H, Ar-H),
8.25 (s, 1H, H-5); 13C NMR (125 MHz, D2O) δ: 55.6 (OCH3),
60.3 (C-5′), 61.0 (C-6″), 70.7 (C-2″, 31P coupled), 71.7 (C-5″, 31P
coupled), 73.0 (C-4″, 31P coupled), 73.9 (C-3′, 31P coupled), 76.5
(C-2′, 31P coupled), 78.0 (C-3″, 31P coupled), 83.8 (C-4′), 91.2
(C-1′, 31P coupled), 98.2 (C-1″), 114.8 (C-5), 120.6, 122.1, 127.5,
147.4, 159.5 (Ar-C); 31P NMR (202.4 MHz, MeOD) δ: −0.55, 0.66
(2P); HRMS (ESI) mass calcd for C20H30N3O19P3 [M]
+,
709.0686, found 709.0691.
( j) 4-(2-Formylphenyl)-triazolophostin (10j). By using
190 mg (0.12 mmol) of 9j, 78 mg (88%) of triazolophostin 10j
was obtained as a white hygroscopic solid: 1H NMR (500 MHz,
D2O) δ: 3.75–3.87 (m, 6H, H-2″, H-5″, H-6A″, H-6B″, H-5A′ and
H-5B′), 4.09–4.11 (m, 1H, H-4″), 4.44 (bs, 1H, H-4′), 4.50 (bs,
1H, H-3″), 4.65–4.68 (m, 1H, H-3′), 5.21 (bs, 1H, H-2′), 5.25 (bs,
1H, H-1″), 6.40–6.42 (m, 1H, H-1′), 7.34 (bs, 1H, Ar-H),
7.46–7.47 (m, 1H, Ar-H), 7.60–7.61 (m, 1H, Ar-H), 7.77 (s, 1H,
H-5 (triazole)), 8.36–8.48 (m, 1H, CH(OH)2);
13C NMR
(125 MHz, D2O) δ: 60.3 (C-5′), 60.9 (C-6″), 71.5 (C-2″,
31P
coupled), 72.0 (C-5″, 31P coupled), 72.2 (C-4″, 31P coupled),
73.4 (C-3′, 31P coupled), 76.1 (C-2′, 31P coupled), 77.1 (C-3″, 31P
coupled), 83.8 (C-4′), 91.2 (C-1′, 31P coupled), 97.8 (C-1″), 121.2
(C-5), 125.8, 126.3, 129.0, 129.3, 130.9, 136.5, 146.7, 147.4, (Ar-
C); 31P NMR (202.4 MHz, D2O) δ: 3.51, 3.63, 4.32; HRMS (ESI)
mass calcd for C20H28N3O19P3 [M]
+, 707.0530, found 707.0549.
(k) 4-(6-Methoxynaphth-2-yl)-triazolophostin (10k). By
using 90 mg (0.057 mmol) of 9k, 42 mg (97%) of triazolophos-
tin 10k was obtained as a white hygroscopic solid: 1H NMR
(500 MHz, MeOD) δ: 3.06 (d, J = 7.7 Hz, 1H, H-2″), 3.69–3.85
(m, 8H, H-5″, H-5A′, H-5B′, H-6A″, H-6B″ and OCH3), 4.13–4.15
(m, 1H, H-4″), 4.32–4.33 (m, 1H, H-4′), 4.53–4.55 (m, 1H, H-3″),
4.70 (t, J = 5.0 Hz, 1H, H-3′), 5.17 (bs, 1H, H-1″), 5.28 (bs, 1H,
H-2′), 6.32 (d, J = 2.7 Hz, 1H, H-1′), 7.05 (dd, J = 9.0, 2.4 Hz, 1H,
Ar-H), 7.15 (d, J = 2.2 Hz, 1H, Ar-H), 7.69 (d, J = 9.0 Hz, 1H, Ar-
H), 7.73 (d, J = 9.0 Hz, 1H, Ar-H), 7.79 (s, 1H, H-5), 8.13 (s, 1H,
Ar-H), 8.57 (s, 1H, Ar-H); 13C NMR (125 MHz, MeOD) δ: 55.9
(OCH3), 61.9 (C-5′), 62.1 (C-6″), 72.6 (C-2″,
31P coupled), 73.5
(C-5″, 31P coupled), 75.0 (C-4″, 31P coupled), 77.0 (C-3′, 31P
coupled), 79.3 (C-2′, 31P coupled), 79.5 (C-3″, 31P coupled), 85.4
(C-4′), 92.9 (C-1′, 31P coupled), 100.7 (C-1″), 106.9 (C-5), 120.4,
121.2, 125.2, 125.5, 126.6, 128.7, 130.4, 130.7, 136.1, 149.4,
Paper Organic & Biomolecular Chemistry
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159.7 (Ar-C); 31P NMR (202.4 MHz, MeOD) δ: 3.605 (2P), 4.393;
HRMS (ESI) mass calcd for C24H32N3O19P3 [M − H]+, 758.0765,
found 758.0785.
8. Biological assay
Ca2+ release from the intracellular stores of saponin-permeabi-
lized DT40 cells expressing only type 1 IP3R was measured
using a low-aﬃnity Ca2+ indicator (Mag-fluo-4) as described
previously.23 Briefly, the ER was loaded with Ca2+ to the steady
state for ∼120 s by addition of 1.5 mM MgATP in medium con-
taining p-trifluoromethoxyphenylhydrazone (FCCP) to inhibit
mitochondria. IP3, AdA or triazolophostins were added with
cyclopiazonic acid (10 µM) to inhibit further Ca2+ uptake. Ca2+
release was assessed 10–20 s after addition of the analog, and
expressed as a fraction of the ATP-dependent Ca2+ uptake.
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